The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market
National Institute of Animal Biotechnology, Hyderabad can now conduct quality checks and consequent lot release of Covid-19 vaccines
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
CDSCO to fast-track trials and approval for COVID19 vaccine
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
Apollo hospital-Hyderabad, Kainos Hospital-Rohtak and Apex Hospital Jaipur have deployed this solution
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
Subscribe To Our Newsletter & Stay Updated
